March 26, 2024
A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.
October 25, 2022
National media outlets highlighted the results of the first-in-human trial of FLASH radiotherapy, led by University of Cincinnati Cancer Center researchers.
November 3, 2022
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, is co-corresponding author of new research in JAMA Oncology that provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
November 7, 2022
MSN India highlighted recent research led by the University of Cincinnati's Trisha Wise-Draper about how immunotherapy and immunosuppression affects COVID-19 severity.
June 6, 2022
The University of Cincinnati's Atsuo Sasaki and an international team of collaborators have been awarded a Human Frontier Science Program research grant to learn more about how cells migrate, with an ultimate goal of developing new treatments to prevent cancer growth and spread.
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
June 4, 2022
The University of Cincinnati's Thomas Herzog, MD, is presenting a poster describing a new immunotherapy trial for platinum-resistant ovarian cancer, called ARTISTRY-7, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
August 10, 2022
Medium featured the research of the University of Cincinnati's Jiajie Diao, PhD, who recently published a paper showing early results that light-activated proteins can help normalize dysfunction within cells.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.